Every Form 4 that Agenus (AGEN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AGEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AGEN filings page.
Agenus Inc granted Chairman and CEO Armen Garo H stock options covering 1,971,500 shares of common stock at an exercise price of $7.78 per share, expiring on August 10, 2036. The award is split into five equal performance-vesting tranches. Each tranche vests only if the share price reaches and sustains, for 30 consecutive days within a five-year performance period, a level equal to 3x, 4x, 5x, 6x, and 8x the $7.78 measurement price, and is also subject to a minimum three-year service requirement.
AGENUS INC director Thomas L. Harrison received a grant of 50,000 Stock Options on August 5, 2026. The options have an exercise price of $7.78 per share, are exercisable for Common Stock, and expire on August 5, 2036. They vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in two equal annual installments thereafter. Following this award, Harrison holds 50,000 options directly.
AGENUS INC director Brian Corvese received a compensatory grant of 100,000 stock options on 2026-08-05. The options have an exercise price of $7.78 per share, expire on 2036-08-05, and were awarded under the company’s 2019 Amended and Restated Equity Incentive Plan. They vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in two equal annual installments.
Agenus Inc. reported that director Timothy Wright received a grant of 50,000 stock options under its 2019 Amended and Restated Equity Incentive Plan. The options have an exercise price of $7.78 per share, expire on August 5, 2036, and vest over three years with one-third after one year and the remainder in two equal annual installments.
AGENUS INC reported that Chief Medical Officer Steven J. O'Day received a grant of 100,000 stock options on 2026-08-05. The options have an exercise price of $7.7800 per share, expire on 2036-08-05, and were awarded under the 2019 Amended and Restated Equity Incentive Plan. They vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in two equal annual installments thereafter.
Agenus Inc. director Susan B. Hirsch received a grant of stock options covering 50,000 shares of common stock on August 5, 2026. The options have an exercise price of $7.7800 per share, expire on August 5, 2036, and were awarded under the 2019 Amended and Restated Equity Incentive Plan. They vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds in two equal annual installments.
Agenus Inc. reported that director and officer Jennifer Buell received a grant of stock options covering 200,000 shares of common stock at an exercise price of $7.78 per share. The options, expiring on August 5, 2036, were awarded under the 2019 Amended and Restated Equity Incentive Plan and vest over three years, with one-third after the first anniversary of the grant date and the remaining two-thirds in two equal annual installments. Following this grant, Buell holds 200,000 stock options directly.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Garo H. Armen received 4,852 shares of common stock on July 10, 2026 as a grant in lieu of cash salary. The shares represent the net amount of his salary for that pay period, are issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan, and are fully vested on the date of issuance. The share amount is based on the $3.35 closing price of Agenus common stock on July 10, 2026. Following this award, Armen holds 371,108 shares directly, plus additional indirect holdings through IRA accounts and trust and partnership entities.
AGENUS INC director Thomas L. Harrison received a grant of 8,547 shares of common stock on July 1, 2026. These shares were acquired under the company’s Board Compensation Election Policy, where directors can take their fees in stock. At a reference price of $3.583 per share, his direct holdings increased to 47,545 shares.
AGENUS INC director Timothy Wright reported a routine compensation grant of Deferred Stock Units. On July 1, 2026, he acquired 2,267.765 Deferred Stock Units, each tied to the company’s common stock on a 1-for-1 basis under the directors’ deferred compensation plan.
The units were valued at $3.583 per Deferred Stock Unit, based on the average closing price of the company’s stock during the prior calendar quarter. Following this award, Wright holds a total of 26,180.771 Deferred Stock Units, which are typically settled in common shares after he ceases serving as a director.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Dr. Garo H. Armen received company stock as salary instead of cash for the pay period ending June 26, 2026. He was granted 5,364 shares of common stock, representing the net amount of his salary, at a reference price of $3.03 per share, which was the closing price on June 26, 2026. These shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan and were fully vested on the date of issuance, bringing his directly held common stock to 366,256 shares. The filing also notes indirect holdings through IRA accounts and through entities such as the Garo Armen 2020 2 Year AG GRAT with 23,950 shares and the Pixie Partners general partnership with 5,000 shares, where he has only a partial pecuniary interest in the partnership’s shares.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. executive and director Dr. Garo H. Armen received 4,925 shares of Common Stock as stock-based salary for the pay period ending June 12, 2026. The shares were valued using the closing price of $3.30 on that date and are fully vested upon issuance under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan. After this grant, Dr. Armen holds 360,892 shares directly, along with additional indirect holdings through IRA accounts and entities referenced in the footnotes.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
AGENUS INC director and officer Garo H. Armen received 4,644 shares of Common Stock as compensation paid in stock instead of cash. The shares were valued at $3.50 per share, equal to the closing price on May 29, 2026, and were fully vested on the grant date.
After this grant, Dr. Armen directly holds 355,967 shares of Common Stock. He also has indirect holdings through IRA accounts and entities, including a GRAT holding 23,950 shares and a general partnership holding 5,000 shares in which he has only a partial pecuniary interest.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Dr. Garo H. Armen received a grant of 4,540 shares of common stock for the pay period ending May 15, 2026, as salary paid in stock instead of cash. The shares were issued fully vested under the company’s 2019 equity incentive plan at a reference price of $3.58, the closing price on May 15, 2026.
Following this grant, Dr. Armen directly holds 351,323 common shares, with additional indirect holdings in IRA accounts and entities such as the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he has only a partial pecuniary interest.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Dr. Garo H. Armen received 4,233 shares of Common Stock as salary paid in stock for the pay period ending May 1, 2026. The shares were valued at $3.84, the closing price of Agenus stock on May 1, 2026, and are fully vested on issuance.
Following this grant, Dr. Armen directly holds 346,783 Agenus shares. He also has indirect holdings through IRA accounts, the Garo Armen 2020 2 Year AG GRAT with 23,950 shares, and Pixie Partners with 5,000 shares, where he has a pecuniary interest in only part of the Pixie position.
AGENUS INC director Susan B. Hirsch received a grant of stock options to acquire 105,000 shares of Common Stock. The options have an exercise price of $3.90 per share and were awarded at no cost as a compensation grant.
The award was granted under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and will vest on the one-year anniversary of the grant date. Following this grant, Hirsch holds stock options covering 105,000 underlying shares directly, with an expiration date in 2036.
AGENUS INC director and officer Jennifer Buell received new stock option awards as part of her equity compensation. On April 24, she was granted options to acquire 5,000 shares of common stock and a separate grant covering 300,000 shares, both with an exercise price of $3.90 per share and expiring on April 24, 2036.
The options were awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vest over three years. One-third of each award vests on April 24, 2027, with the remaining two-thirds vesting in equal quarterly installments thereafter. These are compensation-related grants rather than open-market purchases or sales.
AGENUS INC Chief Medical Officer Steven J. O'Day received two stock option awards covering a total of 165,333 shares of common stock. Both option grants have an exercise price of $3.90 per share and expire on April 24, 2036.
One option for 95,333 shares was awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vests over three years, with one-third vesting on April 24, 2027 and the remainder in equal quarterly installments thereafter. A second option for 70,000 shares was granted under the same plan in lieu of the 2025 annual cash bonus and vests in full on May 24, 2026.
AGENUS INC director Thomas L. Harrison received a compensation-related stock option grant rather than making an open-market trade. On the grant date, he was awarded options to acquire 122,500 shares of Common Stock at an exercise price of $3.90 per share, expiring on April 24, 2036. The filing shows he holds options for 122,500 shares after this grant, and a footnote explains the award was made under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and will vest on the one-year anniversary of the grant date.
AGENUS INC director Timothy Wright received a stock option grant as equity compensation. The award covers 105,000 shares of common stock at an exercise price of $3.90 per share, expiring on April 24, 2036. The option was granted under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vests on the one-year anniversary of the grant date. Following this grant, Wright holds stock options for 105,000 underlying shares directly.
AGENUS INC principal accounting officer Austin Charette received two stock option awards as compensation. On April 24, 2026, Charette was granted options to purchase 17,619 shares of common stock at an exercise price of $3.90 per share, expiring on April 24, 2036. These options were awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vest over three years, with one-third vesting on April 24, 2027 and the remainder in equal quarterly installments.
Charette also received an additional option grant covering 5,000 shares of common stock at the same $3.90 exercise price, also expiring on April 24, 2036. This second grant was awarded in lieu of the 2025 annual cash bonus and vests in full on May 24, 2026. Both transactions are compensation-related grants, not open-market purchases or sales.
Agenus Inc. director and officer Armen Garo H received three stock option awards on April 24, 2026. Each option allows him to purchase Agenus common stock at an exercise price of $3.90 per share and expires on April 24, 2036. One award is scheduled to vest over three years beginning April 24, 2027, and another was granted in lieu of his 2025 annual cash bonus and will vest in full on May 24, 2026.
Agenus Inc. director Brian Corvese received a grant of 210,000 stock options for Agenus Inc. common stock. The options were awarded on April 24, 2026 under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan at an exercise price of $3.90 per share.
The award vests on the one-year anniversary of the grant date and expires on April 24, 2036. After this grant, Corvese holds 210,000 stock options directly. This is a compensation-related award rather than an open-market share purchase or sale.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Dr. Garo H. Armen received 3,403 shares of Common Stock as compensation for his salary for the pay period ending April 17, 2026. His salary is being paid in stock, in lieu of cash, under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan, and these shares are fully vested on the date of issuance.
The shares were valued at $4.79 per share, the closing price of Agenus Common Stock on April 17, 2026. After this grant, Dr. Armen directly holds 342,550 shares, and he also has indirect holdings through IRA accounts and trusts/partnerships, where he has varying degrees of investment authority and pecuniary interest.
HARRISON THOMAS L reported acquisition or exercise transactions in this Form 4 filing.
AGENUS INC director Thomas L. Harrison received 9,228 shares of common stock as a grant under the company’s Board Compensation Election Policy. These shares represent director fees taken in stock rather than cash at an average price of $3.319 per share. After this award, Harrison directly holds 38,998 common shares.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
AGENUS INC director and officer Garo H. Armen received 4,629 shares of Common Stock as fully vested compensation in lieu of cash salary for the pay period ending April 3, 2026. The shares were valued using the $3.33 closing price on April 2, 2026. After this grant, he directly holds 339,147 shares of Agenus common stock. He also has indirect holdings, including 31,298 shares in IRA accounts and 28,950 shares through a GRAT and a partnership in which he has investment authority and a partial pecuniary interest.
Agenus Inc. director Timothy Wright received a grant of Deferred Stock Units as part of his board compensation. On April 1, 2026, he acquired 2,448.256 Deferred Stock Units, each tied to one share of Agenus common stock under the company’s Directors' Deferred Compensation Plan.
Following this award, Wright holds a total of 26,361.262 Deferred Stock Units. These units generally convert into the same number of common shares, typically when he ceases to serve as a director. The April 1, 2026 units were valued at $3.319 each, based on the average closing price of Agenus common stock during the prior calendar quarter.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Garo H. Armen received 3,983 shares of Common Stock as fully vested compensation, in lieu of cash salary, for the pay period ending March 20, 2026. The shares were valued at $3.71, the closing price on March 20, 2026, and issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan. Following the grant, he holds 334,518 shares directly, plus additional indirect holdings through IRA accounts and entities including the Garo Armen 2020 2 Year AG GRAT and Pixie Partners.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
AGENUS INC director and officer Garo H. Armen received 4,994 shares of common stock on March 6, 2026 as a stock-paid salary award. The shares were valued at $2.96 per share, the closing price of Agenus common stock on March 6, 2026, and represent his net salary for the pay period ending that date.
After this grant, Dr. Armen directly held 330,535 Agenus common shares. Additional shares are held indirectly in his IRA accounts and through entities such as the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he has investment authority or a partial pecuniary interest.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Garo H. Armen received a stock award of 4,829 shares of common stock as salary paid in stock for the pay period ending February 20, 2026, valued at $3.06 per share and fully vested on issuance, increasing his direct holdings to 325,541 shares.
He also reports indirect ownership of 31,298 shares held in his IRA accounts and 28,950 shares held through the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he has only a partial pecuniary interest.
Agenus Inc. Chairman and CEO Garo H. Armen received 5,027 shares of common stock on February 6, 2026 as salary paid in stock instead of cash, at a reference price of $2.94 per share. These fully vested shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan and increased his directly held common stock to 320,712 shares.
In addition, the filing notes 31,298 shares held in Dr. Armen’s IRA accounts and 28,950 shares held through entities including the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he has investment roles and a limited pecuniary interest.
Agenus Inc. director and Chairman/CEO Garo H. Armen reported receiving 4,562 shares of Agenus common stock on January 23, 2026. The shares were issued at $3.24 per share, which was the closing price of the stock on that date, and represent his net salary for the pay period ending January 23, 2026, paid in stock instead of cash under the company’s 2019 equity incentive plan. After this transaction, Dr. Armen directly beneficially owned 315,685 Agenus common shares, with additional indirect holdings reported through IRA accounts and a trust/general partnership structure described in the footnotes.
Agenus Inc. Chairman and CEO Garo H. Armen, who also serves as a director, reported receiving 3,780 shares of Agenus common stock on January 9, 2026. According to the disclosure, at his request and with compensation committee approval, his salary for the pay period ending that date is being paid in stock instead of cash, with these shares fully vested on issuance and valued at the closing price of $3.91 per share on January 9, 2026.
After this stock-salary grant, Dr. Armen directly holds 311,123 shares of Agenus common stock. He also has indirect holdings, including 31,298 shares in IRA accounts and 28,950 shares held through the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he is trustee or general partner and has a pecuniary interest in only a portion of certain shares.
AGENUS INC reported an insider equity transaction by its Chairman and Chief Executive Officer, Garo H. Armen, who is also a director. On December 26, 2025, Dr. Armen received 4,942 shares of common stock as payment of his salary for the pay period ending that day, instead of cash. These shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan and were fully vested on the date of issuance, at a reference price of $3.31 per share, which was the closing price of the common stock on that date.
Following this transaction, Dr. Armen beneficially owned 307,343 shares of Agenus common stock directly. He also held shares indirectly, including amounts in his IRA accounts and interests in entities such as the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he has only a partial pecuniary interest.
Agenus Inc. reported that Chairman and Chief Executive Officer Garo H. Armen received 4,316 shares of common stock on 12/12/2025 as payment of his salary in stock, in lieu of cash, at his request and with Compensation Committee approval. The shares were valued at $3.79, the closing price of Agenus common stock on December 12, 2025, and are fully vested on the date of issuance under the company’s 2019 Equity Incentive plan. After this transaction, Dr. Armen directly holds 302,401 Agenus shares, in addition to indirect holdings through IRA accounts and a trust and partnership structure.
Agenus Inc. (AGEN) reported that Chairman and CEO Garo H. Armen received part of his compensation in stock instead of cash. On 11/14/2025, he was issued 3,769 shares of common stock as salary for the pay period ending that date, under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan. The shares were valued using the $4.34 closing price of Agenus common stock on 11/14/2025 and are fully vested on the date of issuance. Following this transaction, Dr. Armen beneficially owns 294,498 shares directly, with additional indirect holdings reported through IRA accounts and entities in which he has a pecuniary interest.
Agenus Inc. (AGEN) reported an insider transaction: Chairman and CEO Garo H. Armen acquired 4,120 shares of common stock on 10/31/2025 at $3.97 per share. The shares were issued as salary paid in stock, fully vested upon issuance, under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan.
After the transaction, Dr. Armen’s direct beneficial ownership was 290,729 shares. He also holds 31,298 shares indirectly through IRA accounts and 28,950 shares indirectly via a GRAT and a partnership, as noted in the filing.
Agenus (AGEN) reported an insider stock compensation event. Chairman and CEO Garo H. Armen received 4,216 shares of Common Stock on 10/17/2025 as salary paid in stock, in lieu of cash, under the Amended and Restated 2019 Equity Incentive plan. The grant was valued using the $3.88 closing price on 10/17/2025 and the shares were fully vested at issuance.
Following the transaction, Dr. Armen beneficially owns 286,609 shares directly, plus 31,298 shares indirectly held in IRA accounts and 28,950 shares indirectly via trust/partnership interests as described in the footnotes.
Garo H. Armen, Chairman and Chief Executive Officer of Agenus Inc. (AGEN), received 3,951 shares of common stock as salary in lieu of cash, issued under the company's equity plan. The shares were issued at the closing price of $4.14 on 10/03/2025 and are fully vested on issuance. After the transaction, Dr. Armen directly beneficially owns 282,393 shares, with additional indirect holdings of 31,298 and 28,950 through retirement accounts and trusts/partnership interests respectively. The filing notes that the stock payment was approved by the Compensation Committee and represents the net amount for the payroll period ending 10/03/2025.
Agenus Inc. (AGEN) director Thomas L. Harrison received 5,780 shares of common stock on 10/01/2025 under the company's Board Compensation Election Policy, electing to take director fees in equity rather than cash. The shares were issued at an average price of $5.01, which the filer says is the average closing price for the quarter preceding issuance. After this transaction, Mr. Harrison beneficially owns 22,079 shares. The Form 4 was filed by an attorney-in-fact on 10/03/2025, and no derivative transactions are reported.
Timothy R. Wright, a director of Agenus Inc. (AGEN), reported acquiring 1,704.928 deferred stock units on 10/01/2025 under the company’s Amended and Restated Directors' Deferred Compensation Plan. Each deferred stock unit converts to one share of common stock on a 1-for-1 basis, and the filing shows 21,872.43 shares beneficially owned by Mr. Wright after the transaction. The filing notes that a prior tranche of deferred stock units was valued at $5.01 per unit on 7/01/2025, and states the October 1, 2025 unit price is the average closing price for the company’s common stock during the calendar quarter immediately preceding that date. The units are typically distributed under the Plan once the director ceases service.
Garo H. Armen, Chairman and CEO of Agenus Inc. (AGEN), reported a non-derivative acquisition on 09/19/2025. At his request and with Compensation Committee approval, Mr. Armen’s salary for the pay period ending September 19, 2025, was paid in stock: 3,734 shares of Common Stock were issued at a closing price of $4.38. Those shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan and were fully vested on issuance. Following the transaction the filing shows Mr. Armen beneficially owning 278,442 shares directly, 31,298 shares held in his IRA accounts, and 28,950 shares indirectly through trustee and partnership arrangements. The form was signed by an attorney-in-fact on 09/23/2025.